Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Imlunestrant and abemaciclib for estrogen receptor-positive breast cancer with minimal residual disease (MIRI)

Phase 2 trial of abemaciclib plus imlunestrant for up to 12 cycles. The registry primary outcome is the rate of ctDNA clearance. ClinicalTrials.gov lists the study as recruiting.

Jonsson Comprehensive Cancer Center